Explanipedia

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS Open

Shalom Haggiag, Luca Prosperini, Massimo Filippi, Maria A. Rocca, Pietro Iaffaldano , et al. · 2025

Importance Early treatment choice in relapsing-remitting multiple sclerosis (RRMS) is prognostically crucial, yet robust comparative data on cladribine vs sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients wit…

CS11 The effect of high-efficacy therapy on disability in children with multiple sclerosis Open

Sifat Sharmin, Izanne Roos, Anneke van der Walt, Helmut Butzkueven, María Trojano , et al. · 2025

Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis Open

Emilio Portaccio, Matteo Betti, Ermelinda De Meo, Luisa Pastò, Elio Prestipino , et al. · 2025

The definition of PIRA combining roving baseline, no relapses 90 days before and 30 days after the event and 24-week confirmation achieved the best predictive value and feasibility, supporting its use in routine practice and research.

The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus Open

Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini , et al. · 2025

Objective To establish recommendations based on an expert consensus on the early and appropriate use of high-efficacy disease-modifying therapies (HE-DMTs) in the management of multiple sclerosis (MS) patients, based on current clinical ev…

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis Open

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesca Caputo, Marta Simone , et al. · 2025

Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Met…

Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis Open

Emilio Portaccio, M. Betti, Ermelinda De Meo, Luisa Pastò, Lorenzo Razzolini , et al. · 2025

Objectives: To assess the impact of age on the superiority of highly effective (HE) disease-modifying treatments (DMTs) compared to platform DMTs in a real-world population of relapsing MS patients (pwMS). Methods: A total of 20,984 pwMS w…

Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials Open

María Trojano, Damiano Paolicelli · 2025

Multiple sclerosis from onset to secondary progression: a 30-year Italian register study Open

Aurora Zanghì, Massimiliano Copetti, Carlo Avolio, Damiano Paolicelli, Marzia Romeo , et al. · 2025

Background Three decades have passed since the initial approval of disease-modifying therapies (DMTs). Ongoing discussion is focused on fundamental aspects of the disease, highlighting a growing division between successes in managing relap…

The Italian Multiple Sclerosis Register Experience With Cladribine Open

Tommaso Guerra, Massimiliano Copetti, Chiara Zanetta, Francesco Patti, Clara Grazia Chisari , et al. · 2025

This study provides Class IV evidence that for patients with relapsing multiple sclerosis, cladribine treatment is associated with a reduction in ARR and PIRA events.

Personalized therapy in multiple sclerosis: an Italian Delphi consensus Open

Claudio Gasperini, Diego Centonze, Antonella Conte, Paolo Gallo, Alessandra Lugaresi , et al. · 2025

Objective The increasing availability of disease-modifying therapies (DMTs) may provide more personalized treatment options for multiple sclerosis (MS) based on various factors, including patients’ characteristics, prognostic indicators, c…

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network Open

Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic , et al. · 2024

Background Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our…

[Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register]. Open

Michela Ponzio, Mario Alberto Battaglia, María Trojano, Marco Salivetto, A D'Ettorre , et al. · 2024

Registers collecting data from clinical practice (real world data) have gained increasing interest in recent years in the scientific, administrative, and regulatory fields. The value of longitudinal data collection in deepening knowledge a…

Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression Open

Emilio Portaccio, Matteo Betti, Ermelinda De Meo, Ilaria Addazio, Luisa Pastò , et al. · 2024

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis Open

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio , et al. · 2024

Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available. We aimed to compare the risk of achie…

Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression Open

Emilio Portaccio, Matteo Betti, Ermelinda De Meo, Ilaria Addazio, Luisa Pastò , et al. · 2024

Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study Open

Clara Grazia Chisari, Umberto Aguglia, Maria Pia Amato, Roberto Bergamaschi, Antonio Bertolotto , et al. · 2024

Big Multiple Sclerosis Data network: an international registry research network Open

Anna Glaser, Helmut Butzkueven, Anneke van der Walt, Orla Gray, Tim Spelman , et al. · 2024

Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries Open

Sifat Sharmin, Izanne Roos, Charles B. Malpas, Pietro Iaffaldano, Marta Simone , et al. · 2024

Predictors of treatment switching in the Big Multiple Sclerosis Data Network Open

Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke van der Walt, Sandra Vukusic , et al. · 2023

Background Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictor…

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom Open

Tim Spelman, William L. Herring, Carlos Acosta, Robert Hyde, Vilija Jokubaitis , et al. · 2023

This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.

Multiple Sclerosis Progression and Relapse Activity in Children Open

Pietro Iaffaldano, Emilio Portaccio, Giuseppe Lucisano, Marta Simone, Alessia Manni , et al. · 2023

Importance Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) are protected against disability because of greater capacity f…

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients Open

Alvino Bisecco, Federica Matrone, Marco Capobianco, Giovanna De Luca, Massimo Filippi , et al. · 2023

Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care Open

Massimo Filippi, Giovanna Borriello, Francesco Patti, Matilde Inglese, María Trojano , et al. · 2023

Background This research aimed to investigate the experience of Neuromyelitis Optica Spectrum Disorders (NMOSD) by integrating the perspectives of patients, caregivers and clinicians through narrative-based medicine to provide new insights…

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) Open

Clara Grazia Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone , et al. · 2023

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis (PPMS) has been evaluated during phase 3 trials that enrolled pat…

Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients Open

Madia Marika Biasi, Alessia Manni, Ilaria Pepe, Chiara Abbatantuono, Daphne Gasparre , et al. · 2023

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study Open

Maria Pia Amato, Roberto Bergamaschi, Diego Centonze, Massimiliano Mirabella, Girolama Alessandra Marfia , et al. · 2023

Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register Open

Paola Mosconi, Tommaso Guerra, Pasquale Paletta, A D'Ettorre, Michela Ponzio , et al. · 2023

Sars-CoV2 infection in pregnant women with multiple sclerosis Open

Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia , et al. · 2023

Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with…

Effectiveness of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter, retrospective, real-world sTudY (OPPORTUNITY) Open

Clara Grazia, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone , et al. · 2023

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis (PPMS) has been evaluated during phase 3 trials that enrolled pat…

Impact of depression on the perception of fatigue and information processing speed in a cohort of Multiple Sclerosis patients Open

Madia Marika Biasi, Alessia Manni, Ilaria Pepe, Chiara Abbatantuono, Daphne Gasparre , et al. · 2023

Background: Information processing speed is commonly impaired in people with multiple sclerosis (PwMS). However, depression and fatigue can affect the cognitive profile of patients: fatigue has a negative impact from the disease’s earliest…

María Trojano YOU? Author Swipe